Insights into all aspects of drug discovery, design and development

Paul Overton

Dr Paul Overton, EVP at Aptuit gained his PhD in cell biology and immunology from the University of Surrey, and has a long career in the drug development industry; first in R&D, and more recently in Contract Research. He has worked with companies such as Guildhay Antisera, Cambridge Life Sciences and LGC Biosciences before moving on to Covance, Huntingdon Life Sciences and now Aptuit. Paul’s in-depth knowledge and expertise has allowed him to develop novel approaches and strategies to improve product development and has been influential in driving the integrated drug development program that Aptuit are so well known for.
Find me on:

Recent Posts

Overcoming tomorrow’s formulation challenges to deliver the medicines of the future

What strategies and technologies should we adopt if we’re to turn today’s promising drug molecules into tomorrow’s safe, effective and affordable medicines? That was the focus of the discussion at Aptuit’s one-day workshop, Improving Candidate Selection Strategies: Translating Molecules into ...

Topics: Drug Development Read More

Translating molecules into medicines: could fresh thinking and collaborative partnerships be the key?

How do we reduce attrition in drug development and ensure scientific innovation translates into safe, effective and affordable treatments for patients? These were the questions at the heart of Aptuit’s one-day think tank event, Improving Candidate Selection Strategies: Translating Molecules into ...

Topics: Drug Development Read More

Drugging the undruggable: how do we put next generation targets within our reach?

What pharmaceutical design strategies must we adopt if we’re to drug the ‘undruggable’ 80% of protein targets thought to be out of reach of current drug discovery techniques? Industry leaders from biotech and pharma gathered at The Marker Hotel, San Francisco, to discuss how to overcome this ...

Topics: Drug Development Read More

How to solve resourcing challenges and gaps in the drug discovery process

Bridging the resource gap in drug discovery The drug discovery process requires a diverse range of expertise, resources, and infrastructure in order to bring a potential drug lead from initial verification right through to clinical trials and commercialization. Unfortunately, many organizations ...

Topics: Drug design and discovery Read More